Stonepine Capital Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Stonepine Capital Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5,515	Closed	-$323K	–	21
2020 Q1	$323K	Sell	5,515 -20,921	-79%	-$2.05M	0.34%	26
2019 Q4	$3.34M	Sell	26,436 -5,732	-18%	-$776K	2.33%	13
2019 Q3	$3.85M	Buy	32,168 +16,693	+108%	+$3.36M	3.73%	11
2019 Q2	$4.62M	Sell	15,475 -279	-2%	-$116K	3.18%	12
2019 Q1	$7.09M	Buy	15,754 +888	+6%	+$389K	4.08%	7
2018 Q4	$6.8M	Buy	14,866 +11,890	+400%	+$7.37M	5.97%	7
2018 Q3	$2.71M	Sell	2,976 -6,408	-68%	-$4.23M	1.58%	19
2018 Q2	$5.51M	Buy	+9,384	New	+$6.12M	3.35%	11

Other funds holding HTGM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Kalos Management Alpharetta, Georgia $46.6M AUM 11.52% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Stonepine Capital Management's HTGM Position: Q2 2020 in Review

Stonepine Capital Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2020, closing a stake of 5,515 shares — an estimated $323K sold.

Stonepine Capital Management first reported a position in HTGM in Q2 2018 and held it in 8 quarters. The position peaked at $7.09M in Q1 2019. 28 funds tracked by Wall St. Rank hold HTGM as of Q2 2020.

Stonepine Capital Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Stonepine Capital Management sold 5,515 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2020, an estimated $323K.
Stonepine Capital Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2018 and held it in 8 quarters.
Stonepine Capital Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $7.09M in Q1 2019.
28 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2020.

Based on Stonepine Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.